Medeon Biodesign Total Liabilities
Medeon Biodesign total liabilities. Based on the latest financial reports, Medeon Biodesign (6499) has total liabilities worth NT$282.14 Million TWD (≈ $8.89 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 6499 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Medeon Biodesign (2017–2025)
Total liabilities of Medeon Biodesign from 2017 to 2025. This chart illustrates how Medeon Biodesign's total liabilities have evolved over time, based on quarterly financial data.
Medeon Biodesign Competitors by Total Liabilities
The table below lists competitors of Medeon Biodesign ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RGC Resources Inc
NASDAQ:RGCO
|
USA | $216.78 Million |
|
Polyram Plastic Industries Ltd
TA:POLP
|
Israel | ILA654.38 Million |
|
Computer Modelling Group Ltd.
TO:CMG
|
Canada | CA$104.20 Million |
|
Junee Limited Ordinary Shares
NASDAQ:JUNE
|
USA | $1.04 Million |
|
Tong Ming Enterprise Co Ltd
TW:5538
|
Taiwan | NT$7.04 Billion |
|
AC Immune Ltd
NASDAQ:ACIU
|
USA | $105.89 Million |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
China | CN¥222.77 Million |
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
China | CN¥1.39 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Medeon Biodesign's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6499 asset base.
Liquidity & Leverage Metrics
Medeon Biodesign Total Liabilities Ratios Explained
Medeon Biodesign total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medeon Biodesign's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medeon Biodesign (2017–2025)
The table below shows the annual total liabilities of Medeon Biodesign from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$243.03 Million ≈ $7.66 Million |
-28.91% |
| 2024-12-31 | NT$341.84 Million ≈ $10.77 Million |
-9.00% |
| 2023-12-31 | NT$375.65 Million ≈ $11.84 Million |
-0.22% |
| 2022-12-31 | NT$376.48 Million ≈ $11.86 Million |
+113.90% |
| 2021-12-31 | NT$176.00 Million ≈ $5.55 Million |
-73.61% |
| 2020-12-31 | NT$666.83 Million ≈ $21.01 Million |
+148.65% |
| 2019-12-31 | NT$268.18 Million ≈ $8.45 Million |
+80.12% |
| 2018-12-31 | NT$148.89 Million ≈ $4.69 Million |
+41.25% |
| 2017-12-31 | NT$105.41 Million ≈ $3.32 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more